Know Labs Inc

Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. It offers its product under the ChromaID brand. The firm operates through the following segments: The Development of Bio-RFID and ChromaID Technology, Particle, Inc. Technology, and AI Sales of NFT Products. Know Labs was founded by Ronald Peter Erickson on October 8, 1998 and is headquartered in Seattle, WA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Know Labs Inc reports improved Q1 performance amidst leadership changes

Know Labs Inc's Q1 2023 earnings call highlighted improved financial performance, progress on Bio-RFID technology, and reassurance of continued momentum despite leadership changes.
The company's strengths lie in innovation, strategic partnerships, and a focus on glucose monitoring, while facing challenges in regulatory approvals and leadership transitions.
Opportunities for Know Labs include diversifying their analyte identification capabilities, leveraging manufacturing partnerships, and capitalizing on the demand for healthcare innovation.

Know Labs reports Q3 loss but shows promise in innovation

Know Labs showcased progress in innovation and research, with a focus on reducing the burn rate. However, challenges include the net loss in Q3 2023 and the need to address market cap concerns. Opportunities exist in leveraging strategic partnerships and potential FDA approvals for future growth.

Know Labs Inc reports Q3 achievements, navigates financial challenges

Know Labs Inc demonstrated strong performance in Q3 2023, with notable achievements in technology development, clinical testing, and IP portfolio expansion.
While facing financial challenges and regulatory hurdles, the company's strategic focus on innovation and cost management positions it for future growth and success.
By leveraging opportunities in data collection, regulatory strategy, and fundraising, Know Labs Inc aims to drive innovation and achieve key milestones in the coming quarters.

Know Labs reports improved FY 2023 performance and unveils Generation 2 device

Know Labs Inc showcased strong financial and operational performance in FY 2023, underpinned by strategic advancements and prudent financial management.
While challenges exist in product development and cost management, the company's focus on innovation and market validation bodes well for future growth.
With a positive outlook for FY 2024 and a clear roadmap for product development, Know Labs is poised to capitalize on market opportunities and drive value for stakeholders.

Know Labs advances noninvasive glucose monitoring with strong IP portfolio

Know Labs Inc (KNW) demonstrated progress in technology development, financial management, and strategic planning during Q1 2024.
While facing challenges in burn rate management and market competition, the company's strong IP portfolio and clinical focus present growth opportunities.
Overall, Know Labs shows promise in innovation, financial stability, and market expansion, positioning itself for future success in the medical device sector.

Know Labs reports strong Q2 performance with promising product launches

Know Labs Inc demonstrated strong performance in Q2 2024, marked by financial improvements, successful product launches, and promising clinical trial results.
The company's strengths lie in innovation, intellectual property, and operational efficiency, positioning them well for future growth and market success.
Challenges around financing, regulatory approvals, and market competition require strategic focus and proactive management to capitalize on growth opportunities.
Opportunities in international expansion, product development, partnerships, and regulatory compliance offer avenues for Know Labs to drive revenue and market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its second quarter of the fiscal year 2023 ended on March 31, 2023, on May 15, 2023, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at www.knowlabs.co/investors, beginning at 1:15 pm PT. Questions to the Company's management team can be submitted throu.

Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2023 Results on May 15, 2023

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of its latest technical feasibility study titled, “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®.” Know Labs is presenting these results today, May 5, at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA. From December 2022 through February.

Know Labs Study Validates Technical Feasibility of its Novel Sensor for Non-Invasive Glucose Monitoring

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of a proof-of-principle study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” conducted in collaboration with Mayo Clinic.

Know Labs Demonstrates Accuracy of Non-Invasive, Bio-RFID Technology with Proof-of-Principle Study

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the establishment of a Scientific Advisory Board (SAB) comprised of distinguished researchers, innovators and experts in medical technology and human health.

Know Labs Forms New Scientific Advisory Board, Appoints Respected Researchers in Medical Innovation as First Members

Know Labs, Inc. (NYSE:KNW ) Q1 2023 Earnings Conference Call February 14, 2023 4:30 PM ET Company Participants Jordyn Hujar - Chief of Staff Ron Erickson - Chairman and Chief Executive Officer Pete Conley - Senior Vice President and Chief Financial Officer Operator Greetings, and welcome to the Know Labs Fiscal Year 2023 First Quarter Earnings Conference Call and Webcast. Please note, this conference call is being recorded.

Know Labs, Inc. (KNW) Q1 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period.

Know Labs, Inc. Reports First Quarter 2023 Results

Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2023 Results on February 14, 2023

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today shared an update on its strategic partnerships with leading experts in data science, sensor technology, product design and regulatory affairs. These strategic partners collectively accelerate Know Labs' progress toward the FDA clearance process for the world's first non-invasive glucose monitoring medical devices.

Know Labs Provides Update on Strategic Partners Engaged in Data Science, Product Engineering and Regulatory Affairs to Accelerate Progress Toward FDA Application

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced changes to its executive leadership team. The new structure will help the Company accelerate the development and delivery of its non-invasive medical diagnostics technology, Bio-RFIDTM, and better position Know Labs for long-term growth and shareholder value creation.

Know Labs Announces Executive Leadership Changes and Confirms 2023 Outlook

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced that Ron Erickson, Founder and Chairman, has been unanimously named Chief Executive Officer by the Company's Board of Directors, while continuing as Chairman of the Board. Former CEO Phil Bosua has stepped down as an executive officer of the Company and Board Member and will become a technology advisor and consultant to Know Labs, effective immediately.

Know Labs, Inc. Names Ron Erickson Chief Executive Officer; Former CEO Phil Bosua Becomes a Technology Consultant to the Company

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been granted a new foundational patent that equates the company's Bio-RFIDTM diagnostic technology to a current reference standard for glucose monitoring, widely used by diabetes researchers, hospital labs and glucose meter manufacturers, and establishes a specific, superior benchmark range of clinical accuracy, known as the MARD or Mean Absolute Relative Difference.

Know Labs, Inc. Expands IP Leadership in Non-Invasive Diagnostics with New High Performance Glucose Sensor Patent

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the quarter and fiscal year ended September 30, 2022.

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2022 Results

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today addressed recent claims by a purported research firm known for fueling and participating in short-selling, which has distributed false and incomplete information about the company in an apparent effort to profit by driving down the company's stock price.

Know Labs, Inc. Addresses False and Incomplete Short Seller's Claims

SEATTLE--( BUSINESS WIRE )--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review updates and results for its fiscal year ended on Sept. 30, 2022, on Dec. 20, 2022, beginning at 1:30 pm PT.

Know Labs, Inc. to Host Review of Fiscal Year 2022 Results on December 20, 2022

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE AMERICAN: KNW), an emerging leader in non-invasive medical diagnostic technology, will present at the second annual Bernstein CGM Disruptors Conference www.bernsteinresearch.com on Friday, Nov. 18, 2022.

Know Labs Participating in Second Annual Bernstein CGM Disruptors Conference

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the closing of its underwritten public offering of 4,140,000 shares of its Common Stock at a public offering price of $2.00 per share, which includes the exercise by the underwriter of its over-allotment option to purchase up to 540,000 shares. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other

Know Labs, Inc. Announces Closing of $8.28 Million Public Offering of Common Stock

Shares of Know Labs (NYSE: KNW ) are trading messily on Friday. The stock is down about 18% so far on the day, as investors size up the current environment.

Know Labs (KNW) Stock Falls on IPO

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $2.00 per share (the "Offering"). The aggregate gross proceeds from the Offering are expected to total $7.2 million before deducting the underwriting discounts and commissions and estimated Offering expenses payable by

News for Know Labs Inc Stock (KNW)